Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Basit Öğe Kaydı
dc.authorscopusid8927152600
dc.authorscopusid56893368500
dc.authorscopusid56195646300
dc.authorscopusid57921609100
dc.authorscopusid51665869400
dc.authorscopusid25225546400
dc.authorscopusid37102664500
dc.contributor.authorÖnlen, Y.
dc.contributor.authorBal, T.
dc.contributor.authorÇabalak, M.
dc.contributor.authorÇuvalcı Öztoprak, N.
dc.contributor.authorSarı, N.D.
dc.contributor.authorKurtaran, B.
dc.contributor.authorTabak, F.
dc.contributor.authorKaraali, Rıdvan
dc.contributor.authorGüner, Rahmet
dc.date.accessioned2023-04-20T08:04:17Z
dc.date.available2023-04-20T08:04:17Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBACKGROUND: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. METHODS: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (?65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. RESULTS: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). CONCLUSION: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
dc.identifier.doi10.5152/tjg.2022.21271
dc.identifier.endpage873
dc.identifier.issn2148-5607
dc.identifier.issue10en_US
dc.identifier.pmid35946896
dc.identifier.scopus2-s2.0-85139571415
dc.identifier.scopusqualityQ3
dc.identifier.startpage862
dc.identifier.trdizinid1134402
dc.identifier.urihttps://doi.org/10.5152/tjg.2022.21271
dc.identifier.urihttps://hdl.handle.net/20.500.11776/11071
dc.identifier.volume33
dc.identifier.wosWOS:000955590200007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.institutionauthorKaraali, Rıdvan
dc.institutionauthorGüner, Rahmet
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectantivirus agent
dc.subjectribavirin
dc.subjectsofosbuvir
dc.subjectadult
dc.subjectaged
dc.subjectchronic hepatitis C
dc.subjectclinical trial
dc.subjectcombination drug therapy
dc.subjectgenetics
dc.subjectHepacivirus
dc.subjecthuman
dc.subjectmale
dc.subjectmulticenter study
dc.subjectprospective study
dc.subjectsustained virologic response
dc.subjecttreatment outcome
dc.subjectturkey (bird)
dc.subjectAdult
dc.subjectAged
dc.subjectAntiviral Agents
dc.subjectDrug Therapy, Combination
dc.subjectHepacivirus
dc.subjectHepatitis C, Chronic
dc.subjectHumans
dc.subjectMale
dc.subjectProspective Studies
dc.subjectRibavirin
dc.subjectSofosbuvir
dc.subjectSustained Virologic Response
dc.subjectTreatment Outcome
dc.subjectTurkey
dc.titleEfficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
11071.pdf
Boyut:
3.15 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu